CPH creso pharma limited
Add to My Watchlist 0.00% ! 0.9¢

Creso Pharma's (CPH) subsidiary Halucenex Life Sciences will...

  1. TheMarketOnline
    7,927 Posts.
    lightbulb Created with Sketch. 1230
    clock Created with Sketch.
    20/09/21
    14:55
    Post #: 56209182
    • Creso Pharma's (CPH) subsidiary Halucenex Life Sciences will work with a Canadian university to develop a capsule drug delivery containing cannabidiol (CBD) or psilocybin
    • Halucenex has signed a Research Collaboration Agreement with Acadia University to develop a product based on nanoemulsion technology
    • CPH says the tech is known for its quick release effect, good bioavailability and rapid onset, with the collaboration to be completed in 2022
    • It adds these product development initiatives are intended to strengthen its intellectual property (IP) and provide an advantage in the growing US market

    Read the Full Article on The Market Herald here
    CPH Price at posting: 11.8¢ Sentiment: None Disclosure: Not Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Locksley significantly enlarges exploration program after historical discovery
right-arrow Created with Sketch.
FBM Assays confirm strong gold anomalism at Canyon within Miriam Project
right-arrow Created with Sketch.
NEWS Gateway acquires interest in strategic Glenburgh South Gold Project in WA
right-arrow Created with Sketch.
NEWS Where the Australian property market resurgence is heading and why it matters now
right-arrow Created with Sketch.
NEWS Strategic investment secured for QLD and NSW bauxite projects
right-arrow Created with Sketch.
NEWS Drilling to commence at FAU’s Gimlet high-grade gold project following approvals
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.